Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis

Table 1 Summary of data points presented in relevant clinical trials

Ref.	Year	Country	Research institution	Study period	MINORS score	IHP patients (n)	Tumor details	Eligibility and exclusion criteria	IHP details and response rate	Morbidity and mortality	Complications and toxicities	Long-term survival	Prognostic factors
Olofsson et al[55]	2014	Sweden	The Swedish National Board of Health and Welfare	April 2005 to March 2011	18	34	Y	Y	Y	Y	Y	Y	Y
Magge et al[56]	2014	United States	University of Pittsburgh Cancer Institute	November 2003 to February 2012	12	91	Y	NR	Y	Y	Y	Y	Y
Fukumoto et al[57]	2014	Japan	The Kobe University Hospital	January 1989 to December 2010	12	68	Y	Y	Y	NR	Y	Y	Y
Alexander et al[58]	2009	United States	NCI	June 1994 to July 2005	12	120	Y	Y	Y	Y	Y	Y	Y
van Iersel et al[59]	2008	Netherlands	Leiden University Medical Center	August 1994 to December 2004	12	105	Y	Y	Y	Y	Y	Y	Y
Rizell et al[60]	2008	Sweden	Sahlgrenska University Hospital	1985 to 2007	11	27	Y	Y	Y	Y	Y	Y	NR
Pingpank et al[61]	2005	United States	NCI	July 2001 to January 2004	12	28	Y	Y	Y	Y	Y	NR	NR
Alexander et al[62]	2003	United States	NCI	December 1997 to August 2002	12	29	Y	Y	Y	Y	Y	Y	Y

Y: Recorded data available; NR: Not reported; NCI: The National Cancer Institute; MINORS: Methodological index for non-randomized studies.